01:57 , Mar 22, 2019 |  BC Innovations  |  Product Development

Regulating regeneration in Europe

As Europe rethinks its policies on regenerative medicine, the question is whether it can regain its footing in a competitive field it once led, given the in-built inconsistencies across the EU’s member states. Europe positioned...
17:04 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Caladrius reports interim Phase II data for Type I diabetes candidate

Caladrius Biosciences Inc. (NASDAQ:CLBS) said recent-onset Type I diabetes candidate CLBS03 was "non-futile as determined by predefined futility criteria for therapeutic effect" in an interim analysis of 55 evaluable patients ages 8-17 in the Phase...
18:00 , Mar 9, 2018 |  BC Week In Review  |  Company News

Caladrius gets late-stage cell therapy from Shire

Shire plc (LSE:SHP; NASDAQ:SHPG) granted Caladrius Biosciences Inc. (NASDAQ:CLBS) an exclusive, worldwide license to data and regulatory filings for a late-stage CD34+ cell therapy program to treat refractory angina. Shire will receive an upfront payment...
21:39 , Sep 29, 2017 |  BC Week In Review  |  Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

Casebia Therapeutics (Cambridge, Mass.) and Seattle Children's Research Institute (Seattle, Wash.) partnered to develop CRISPR- Cas9 (CRISPR-associated protein 9)-edited Tregs to treat and prevent autoimmune diseases. The partners will build on technologies developed in the...
22:00 , Sep 27, 2017 |  BC Extra  |  Company News

Casebia, Seattle Children's partner to develop gene-edited Tregs

Casebia Therapeutics (Cambridge, Mass.) and Seattle Children's Research Institute (Seattle, Wash.) partnered to develop CRISPR- Cas9 (CRISPR-associated protein 9)-edited Tregs to treat and prevent autoimmune diseases. The partners will build on technologies developed in the...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
00:36 , Mar 10, 2017 |  BC Week In Review  |  Company News

CIRM funding news

CIRM awarded $32.6 million in grants to fund clinical trials and R&D. Caladrius will receive up to $12.2 million for its ongoing Phase II trial of autologous T regulatory cells ( CLBS03 ) to treat...
23:08 , Nov 2, 2016 |  BC Week In Review  |  Clinical News

CLBS03: Ph II ongoing

An independent DSMB recommended continuation to the second cohort of the double-blind, placebo-controlled, U.S. Phase II T-Rex trial evaluating single infusions of 2 dose levels of CLBS03 in patients ages 12-17. The decision was based...
19:52 , Oct 13, 2016 |  BC Innovations  |  Emerging Company Profile

Turning on Tregs

Although expanding Tregs to treat autoimmune diseases offers a safer alternative to general immunosuppression, the challenge has been to target only those cells, and avoid stimulating T cells that will exacerbate disease. By homing in...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Financial News

Caladrius Biosciences completes direct public offering

Caladrius Biosciences Inc. (NASDAQ:CLBS), New York, N.Y.   Business: Gene/Cell therapy, Cardiovascular, Endocrine/Metabolic   Date completed: 2016-09-15   Type: Direct public offering   Raised: $4 million   Shares: 847,458   Price: $4.72   Shares after...